Screener
Kyverna Therapeutics, Inc. KYTX Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Kyverna Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: Kyverna Therapeutics, Inc.’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:08 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219397
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $32,194 | $124,093 |
| Available-for-sale marketable securities | 204,252 | 155,160 |
| Prepaid expenses and other current assets | 5,280 | 3,700 |
| Total current assets | 241,726 | 282,953 |
| Restricted cash | 551 | 551 |
| Property and equipment, net | 1,343 | 1,546 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Kyverna Therapeutics, Inc.'s cash & equivalents?
- Kyverna Therapeutics, Inc. (KYTX) reported cash & equivalents of $32.19M in Q1 2026.
- How has Kyverna Therapeutics, Inc.'s cash & equivalents changed year-over-year?
- Kyverna Therapeutics, Inc.'s cash & equivalents decreased by 43.4% year-over-year, from $56.87M to $32.19M.
- What is the long-term trend for Kyverna Therapeutics, Inc.'s cash & equivalents?
- Over 2 years (2023 to 2025), Kyverna Therapeutics, Inc.'s cash & equivalents has grown at a 89.3% compound annual growth rate (CAGR), from $34.65M to $124.09M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Kyverna Therapeutics, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude